Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Core Insights - Jyong Biotech Ltd. has completed patient enrollment in its Phase II clinical trial for MCS-8, an investigational drug candidate aimed at prostate cancer prevention, with over 700 high-risk subjects enrolled [1][3] - The trial is randomized and placebo-controlled, taking place across 20 hospitals in Taiwan with the involvement of more than 130 urologists [2] - The company has expressed satisfaction with reaching this milestone, highlighting the team's professionalism and dedication despite challenges posed by the COVID-19 pandemic [3] Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases [4] - Established in 2002, the company has developed integrated capabilities across all key drug development functions, including discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - The company aims to provide first-class innovative drugs to meet health needs and aspires to be a respected organization in the industry [4]